ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 214 filers reported holding ROYALTY PHARMA PLC in Q1 2021. The put-call ratio across all filers is 1.03 and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $60,696,120 | -13.2% | 2,236,396 | -1.7% | 0.04% | -7.0% |
Q2 2023 | $69,905,349 | -24.3% | 2,274,100 | -11.3% | 0.04% | -29.5% |
Q1 2023 | $92,379,414 | -10.1% | 2,563,995 | -1.4% | 0.06% | -16.4% |
Q4 2022 | $102,766,965 | -7.6% | 2,600,501 | -53.0% | 0.07% | -12.0% |
Q3 2022 | $111,175,064 | -14.9% | 5,528,162 | +77.9% | 0.08% | -7.8% |
Q2 2022 | $130,610,000 | +20.5% | 3,106,601 | +11.6% | 0.09% | +73.1% |
Q1 2022 | $108,417,000 | +5.9% | 2,782,826 | +8.3% | 0.05% | +20.9% |
Q4 2021 | $102,423,000 | +20.0% | 2,570,179 | +8.8% | 0.04% | +16.2% |
Q3 2021 | $85,373,000 | -44.4% | 2,362,294 | -36.9% | 0.04% | -43.9% |
Q2 2021 | $153,525,000 | +183.8% | 3,745,414 | +202.0% | 0.07% | +164.0% |
Q1 2021 | $54,091,000 | -78.0% | 1,240,054 | -74.7% | 0.02% | -78.1% |
Q4 2020 | $245,330,000 | +23.4% | 4,901,700 | +3.7% | 0.11% | +9.6% |
Q3 2020 | $198,766,000 | -9.2% | 4,724,644 | +4.8% | 0.10% | -15.4% |
Q2 2020 | $218,822,000 | – | 4,507,138 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |